Business Wire

Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

Share

Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529).

The Phase I clinical trial is a randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.1 The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs).

In an experiment conducted in partnership with the National Institutes of Health (NIH), CT-P63 showed strong neutralising activity against the Omicron variant based on structural analysis by X- ray crystallography and neutralisation data from pseudo- virus testing. Celltrion anticipates results of the SARS-CoV-2 Omicron variant assays and animal model studies by the end of the first quarter this year.

In order to elicit potent neutralising antibody response against the new emerging variants, Celltrion previously identified a total of 38 potent neutralising antibodies against SARS-CoV-2 in which antibody candidate No. 32 (CT-P63) produced high neutralisation titres against new emerging strains. CT-P63 has previously been demonstrated to have neutralising activity against the most common variants, including the Alpha, Beta, Gamma and Delta variants.

“The positive results demonstrate the potential of our cocktail therapy to retain neutralising ability against the Omicron variant” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “We are confident that our antibody platform including Regkirona and CT-P63 will provide significant benefit for patients with COVID-19. Regkirona is given to a patient intravenously, so the drug could effectively treat patients hospitalised with COVID-19 at an early stage, while the nebulised cocktail therapy could address patients’ unmet needs for at- home treatment. We plan to discuss large- scale clinical trial for our nebulised cocktail therapy (CT-P63 in combination with Regkirona™) with regulatory agencies worldwide in the near future.”

- ENDS -

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.

About regdanvimab (CT-P59)

CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. In vitro and in vivo pre- clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD and significantly neutralises the wild type and mutant variants of concern. In in vivo models, CT-P59 effectively reduced the viral load of SARS-CoV-2 and inflammation in lung. Results from the global phase I and phase II/III clinical trials of CT-P59 demonstrated a promising safety, tolerability, antiviral effect and efficacy profile in patients with mild-to-moderate symptoms of COVID-19.2 The EC granted marketing authorisation for Celltrion’s regdanvimab following positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2021.

About CT-P63

CT-P63 is a monoclonal antibody targeting SARS-CoV-2 spike receptor binding domain (RBD) as a treatment for COVID-19 infection. CT-P63 is currently being developed as a potential treatment for SARS-CoV-2 infection.

About nebulised formulation

The nebulised formulation of the monoclonal antibody not only targets SARS-CoV-2 spike receptor binding domain (RBD) and elicit neutralising antibody response but it also has ‘trapping’ mechanism of action and thereby neutralises and traps in mucus with exceptional potency. The muco-trapping antibody platform directly traps the virus in airway mucus, preventing the local spread of the infection, and quickly eliminating the virus from the lungs through the body's natural ability to clear mucus. Nebulized formulation can be readily self-administered by patients, extend critical drug supplies to more patients by reducing the dosage needed, and does not place excessive demands on healthcare staff and infusion clinic space that intravenous (IV) drugs do.

FORWARD LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

____________________________

1 ClinicalTrials.gov. To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects. Available at: https://clinicaltrials.gov/ct2/show/NCT05017168#wrapper [Last Accessed January 2022]
2 Celltrion Data on file

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Barber
hbarber@hanovercomms.com
+44 (0) 07759 301620 

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Elliptic Launches Market Intelligence Unit and Announces New Proposition for Crypto Traders17.1.2022 12:10:00 CET | Press release

Elliptic, the leading provider of on-chain blockchain analytics, today announces the launch of its market intelligence unit; a second line of business for the organization that is focused on leveraging Elliptic’s best-in-class identity graph to build new propositions and use cases for businesses trading crypto. The new unit, led by Elliptic co-founder James Smith and Laura Coffey, will harness Elliptic’s dataset as an intrinsically valuable data layer for the burgeoning institutional crypto trading market. The data will provide access to the broadest asset coverage of on-chain identity metrics in the industry, allowing traders to: Forecast: Utilize real insights behind the movements of money to access fundamental activity metrics for a wide range of cryptoassets React: Profile the different types of actors behind deposits, withdrawals and other transactions in real-time to assess the motivations behind market-moving activity Analyze: Explore flows between businesses and other types of

38% of Supplier Survey Respondents Use Early Payment to Manage Working Capital, Up From 19% In 201717.1.2022 11:00:00 CET | Press release

38% of respondents take early payments monthly in 2021, up from 19% in 2017, according to a supplier sentiment survey conducted by Taulia, the leader in working capital technology solutions. Taulia’s global supplier sentimentsurveyhas been conducted annually since 2017 and reflects the views of nearly 80,000 respondents over a five-year period. There has been growing interest from suppliers in regularly receiving early payment once an invoice is approved as an alternative source of finance. In 2021, one-fifth (22%) of suppliers were interested in receiving early payment every time for every customer, compared to 15% in 2017. The supplier's reasons for taking early payments varied. In 2021, the main reasons for their interest in early payments were*: Cash flow gap (49%) Collections/payment predictability (27%) Working capital needs (21%) Ease of use (18%) Reduce DSO (7%) There is also a clear progression towards better behaviour from businesses with a welcome decrease in late payment, w

Gunma Prefecture's Geographical Indication “GI Tone-Numata” Sake Kicks Off Its Overseas Sales on January 17!17.1.2022 09:00:00 CET | Press release

Sake’s geographical indication, “GI Tone-Numata,” which consists of four sake breweries in the Tone-Numata area of Gunma Prefecture in Japan, requires that the breweries make the most of the local water and climate, and that the type of rice used as the raw material be one of the following: Yukihotaka, Gohyakumangoku, or Koshihikari. In addition, only yeast from the local area (Gunma KAZE yeast, Gunma G2 yeast, and brewer's house yeast) can be used, and vintage can be indicated under certain conditions, so only those that meet the extremely strict criteria are certified. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006144/en/ 7 types of GI Tone-Numata certified sake (Photo: Business Wire) According to Mr. Shinya Tasaki, Chairman of the Japan Sommelier Association, "GI Tone-Numata is equivalent to PDO in Europe or AOC in French wine and is expected to attract worldwide attention in the future." On January 17, "GI Tone

EcoFlow Launches the DELTA Pro, its Pioneering Portable Power Station, in Europe17.1.2022 08:00:00 CET | Press release

EcoFlow, a portable power and renewable energy solutions company, has launched the industry-leading DELTA Pro portable home battery in Europe. Originally a Kickstarter campaign, it smashed records to become the most-funded tech project at the time and still ranks sixth among all projects to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220116005003/en/ EcoFlow DELTA Pro Portable Home Battery (Photo: Business Wire) With a base capacity of 3.6kWh and expandable to 25kWh, the DELTA Pro is the industry’s first portable home battery and can provide multiple days’ worth of backup energy to families in the case of emergencies. In September 2021, EcoFlow launched the DELTA Max and the DELTA mini in Europe, both of which are designed to offer backup power for shorter blackout periods. “DELTA Pro’s highly successful Kickstarter campaign overwhelmingly demonstrates the consumer desire for portable clean energy power and storage

TaiwanPlus Features Namewee and ABAO’s Music-Creation Journey on Its Indie Music Docuseries, “Road to Legacy”17.1.2022 07:51:00 CET | Press release

TaiwanPlus, a new global English-language video streaming platform, launches a 2022 TaiwanPlus Original Series titled “Road to Legacy,” which is a 10-episode docuseries detailing the journey to fame of these 10 bands in Taiwan. On January 17, 2022, TaiwanPlus holds the world premiere at Legacy Taipei, with the docuseries launched exclusively and free to stream worldwide via www.TaiwanPlus.com on the same day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220116005075/en/ The TaiwanPlus Original Series will be released in three installments, kicking off with the episodes on Tizzy Bac, 88BALAZ and Nighteentael on January 17th. (Graphic: Business Wire) Since its inception, “TaiwanPlus strives to provide a platform to showcase the diverse, creative culture that flourished under Taiwan’s vibrant democracy. Following the positive reception from the TaiwanPlus Film Festival, which was an online curation of 10 iconic Taiwanese film

Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvement17.1.2022 06:16:00 CET | Press release

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global optical semiconductor company, announced on the 17th that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220116005060/en/ Experimental results on the correlation between lighting and myopia, conducted by Seoul Semiconductor and Singapore Eye Research Institute (Graphic: Business Wire) In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D, Seoul Semiconductor has been conducting experiments with Seoul National University, Basel University, and Harvard University since 2017. This time, with Singapore SERI, the effect of natural lighting on myopia improvement was tested. In this experiment, chicks, whose eyes are similar to humans’, were exposed to different lightings and then the length of th

Megaport Announces Expansion to Mexico, Bringing Network as a Service (NaaS) and Direct Access to Leading Cloud Services to KIO Networks16.1.2022 22:00:00 CET | Press release

Megaport Limited (ASX: MP1) ("Megaport"), a global leading Network as a Service (NaaS) provider, today announces plans to expand services to Mexico via a partnership with KIO Networks, the country’s largest data centre provider. Cloud connectivity services to Microsoft Azure and Google Cloud are expected to be available in March 2022 to local enterprises via on-ramps from KIO Networks’ data centres in Mexico City and Queretaro, subject to approvals. Customers of KIO Networks in Mexico will be able to access Megaport’s leading ecosystem of more than 700 enabled data centres worldwide and over 360 service providers, including 230+ cloud on-ramps from the world's leading clouds such as AWS, Google Cloud, Microsoft Azure, IBM Cloud, and Oracle Cloud. Businesses in Mexico can seamlessly and directly connect to cloud and IT services on a global level without the need to manage complex network infrastructure. According to IDC, Mexico is the second largest market in Latin America when it comes